Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $11.25, but acceptable to hold if already in. Reason: Market cap $0.94B below $1B minimum.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is... Read more
Hold if already holding. Not a fresh buy at $11.25, but acceptable to hold if already in. Reason: Market cap $0.94B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.94B below $1B minimum. Not in investable universe. Score 5.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Corvus Pharmaceuticals, Inc.
Latest news
- NEWS Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals — benzinga Jun 9, 2026 positive
- NEWS Corvus Pharma Q1 EPS $(0.15), Inline — benzinga May 7, 2026 neutral
- NEWS Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Gol — benzinga Apr 17, 2026 positive
- NEWS Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings — benzinga Apr 17, 2026 neutral
- NEWS Autoliv Posts Upbeat Q1 Results, Joins United Airlines, Royal Caribbean Cruises And Other Big Stocks Moving Higher On Fr — benzinga Apr 17, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $11.25, but acceptable to hold if already in. Reason: Market cap $0.94B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.94B below $1B minimum. Not in investable universe. Target $29.00 (+157.8%), stop $10.51 (−7.0%), A.R:R 12.4:1. Score 5.2/10, moderate confidence.
Take-profit target: $29.00 (+159.9% upside). Target $29.00 (+157.8%), stop $10.51 (−7.0%), A.R:R 12.4:1. Stop-loss: $10.51.
Market cap $0.94B below $1B minimum.
Corvus Pharmaceuticals, Inc. trades at a P/E of N/A (forward -11.8). TrendMatrix value score: 9.0/10. Verdict: Hold.
13 analysts cover CRVS with a consensus score of 4.2/5. Average price target: $33.
What does Corvus Pharmaceuticals, Inc. do?Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product...
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.